Tina Garyantes work email
- Valid
- Valid
- Valid
- Valid
- Valid
Tina Garyantes personal email
Tina Garyantes phone numbers
Innovative Leader with an exceptional track record of advancing compounds into the clinic and ideas into products. Extensive global and domestic experience ranging from large pharma to emerging biotechs. Enjoys strategic partnering and leading diverse teams of scientists and engineers across disciplines.• Past and current board member and advisor to multiple companies and governmental entities• Angel investor• Advanced NCE from initial synthesis into the clinic in 14 months• Partnered single preclinical asset for terms typical of a molecule with clinical POC• Invented, developed and out licensed well-less 1536 “virtual well” plate • Established multi-functional phenotypic discovery platform which advanced projects at over twice the rate of traditional target based projects• Founded platform based biotech and negotiated collaborations leading to merger• Designed and delivered first clinical analyzer for DNA fine structure to the Mayo Clinic• Improved project progression from <10% to >90% in 2 years while retaining all team members • Founded Merck's Technology Symposium that continues to today• Caltech PhD in Biophysics, BSE in Bioengineering from the University of Pennsylvania• PerkinElmer International Life Sciences Award• Outstanding Women in Biomedical Research Award
-
Chief Operating OfficerLinnaeus Therapeutics, Inc. Dec 2022 - PresentHaddonfield, New Jersey, Us
-
Senior Vice PresidentLinnaeus Therapeutics, Inc. Aug 2018 - Dec 2022Haddonfield, New Jersey, UsLinnaeus Therapeutics is a developing novel GPCR modulators for the treatment of cancer. Our most advanced molecule is a GPER agonist that is completing dose escalation. It has proven to provide some advanced cancer patients with clinical benefit while being extremely safe and tolerable. I am enjoying running R&D as well as operation aspects such as financial modeling and pharmaceutical partnering.
-
Vice President, TherapeuticsChromocell Jan 2013 - Jul 2018North Brunswick, Nj, UsLeads R&D teams that have successfully identified and advanced an NCE into the clinic and obtained FEMA approval for multiple flavors. Led successful partnering and negotiation efforts that kept company afloat and spearheaded ongoing Business Development and Life Cycle Management efforts. • Partnered single preclinical pain asset for milestones worth over $500 million, double-digit royalties, and co-development and co-promotion rights while retaining non-human and non-therapeutic rights• Progressed NaV1.7 program into Phase 1 from initial synthesis in 3 years with team of 6 people • Authored non-clinical sections of pre-IND briefing booklet, IND, Fast Track application and ongoing IND updates to garner FDA approval and insure continued compound advancement• Led internal non-clinical toxicology, CMC and regulatory efforts• Advanced therapeutic pipeline by preparing an IV therapeutic for IND, developing a veterinary therapeutic and several other early discovery programs -
Founder And CeoMaxsar Biopharma Mar 2012 - Dec 2012Founded biotech focused on high throughput biologically inspired synthesis to maximize exploration of structure-activity relationships with 3 colleagues from Sanofi• Developed platform for rapid exploration of novel chemistry in biologically privileged space to quickly overcome issues in advanced lead and candidate molecules• Won research collaborations with a large pharmaceutical company and a biotech• Negotiated merger of MaxSAR into Chromocell
-
Global Head Lgcr / Senior DirectorSanofi-Aventis U.S. Llc Aug 2000 - Mar 2012Bridgewater, New Jersey, UsProgressed in company through 8 promotions to ultimately lead 100+ global research department. Managed in vitro biology, HTS, ADMET, scientific computing, chemistry, analytical, global data management, cell and protein production, and chemical library teams. Scientific strategy roles in Oncology, Fibrosis and Wound Repair (FWR) and member of leadership teams or project progression committees for Oncology, Immunology and Inflammation, FWR, CNS, Internal Medicine, and Aging. • Approved new lead identification plans (>50/year) from all global therapeutic areas• Revamped approach to HTS to increase success of early projects from near zero to 90%, resulting in 80% of the portfolio being derived from HTS and all screening transferring from the therapeutic area to my team• Established phenotypic screen based drug discovery best practices that typically identified mechanism of action for >50% of compounds at the end of the screen and fostered a fivefold growth in the phenotypic portfolio• Organized three-way collaboration that improved HCS workflow with third party image analysis yielding >5x time savings and reducing image analysis time >10x • Created or key contributor to global teams setting or influencing scientific direction for protein-protein interactions, assay quality improvements, early ADMET testing, screening outcome analysis and singleton follow up among others• Received multiple special achievement awards for supporting projects transitioning into Development• Retained entire department during Sanofi merger with Aventis -
Research FellowMerck Research Laboratories 1996 - 2000Rahway, New Jersey, Us• Conceived, developed, patented and out-licensed 1 ul 1536 “virtual well” plates to Becton Dickinson, that are currently being sold by Curiox • Created companywide Technology Symposium which has endured to present and fosters global collaboration• Evaluated, negotiated, and helped implement multimillion dollar collaboration with Aurora Biosciences. Identified and mitigated potential collaboration risks prior to installation -
Scientist / Systems EngineerChiron/Ciba Corning Diagnostics 1992 - 1996Technical and project management responsibility for twelve scientists/engineers, promoted twice• Developed and delivered first clinical instrument to the Mayo Clinic for fine structure analysis of DNA • Realized 50% performance improvement upon automation, >99% specificity and sensitivity
-
Group LeaderCryopharm 1990 - 1991Group Leader, Process Development supervising five people freeze-drying red blood cells• Designed and built a clean room, invented and patented bags for lyophilization of blood• Researched and wrote feasibility study for new immune-diagnostic product lines
Tina Garyantes Skills
Tina Garyantes Education Details
-
CaltechBiophysics -
University Of PennsylvaniaBioengineering
Frequently Asked Questions about Tina Garyantes
What company does Tina Garyantes work for?
Tina Garyantes works for Linnaeus Therapeutics, Inc.
What is Tina Garyantes's role at the current company?
Tina Garyantes's current role is COO at Linnaeus Therapeutics.
What is Tina Garyantes's email address?
Tina Garyantes's email address is ti****@****ell.com
What is Tina Garyantes's direct phone number?
Tina Garyantes's direct phone number is +173256*****
What schools did Tina Garyantes attend?
Tina Garyantes attended Caltech, University Of Pennsylvania.
What are some of Tina Garyantes's interests?
Tina Garyantes has interest in Children.
What skills is Tina Garyantes known for?
Tina Garyantes has skills like Drug Discovery, Biotechnology, Cell Biology, Drug Development, Pharmaceutical Industry, Pharmacology, Life Sciences, Biomarker Discovery, Clinical Development, Change Management, Global Leadership, Strategic Leadership.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial